<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04274608</url>
  </required_header>
  <id_info>
    <org_study_id>TanTockSengH</org_study_id>
    <nct_id>NCT04274608</nct_id>
  </id_info>
  <brief_title>Intra-gastric Fundal and Body Injection of Botulinum Toxin A for Weight Loss, a Randomized Controlled Trial</brief_title>
  <official_title>Intra-gastric Fundal and Body Injection of Botulinum Toxin A for Weight Loss, a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tan Tock Seng Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tan Tock Seng Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled trial to compare intra-gastric injection of Botulinum Toxin A
      (Botox; Allergan Inc. Irvine, Ca, USA) against non-surgical management for obesity (i.e.
      exercise/diet). Our hypothesis is that intra-gastric injection of Botox into the fundus and
      body of the stomach will result in greater weight loss than just exercise and diet alone.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized Controlled Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight loss</measure>
    <time_frame>1 year</time_frame>
    <description>Examine the average weight loss</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to weight regain following a single injection of intra-gastric Botox</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gut hormone level</measure>
    <time_frame>1 year</time_frame>
    <description>Ghrelin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut hormone level ( Leptin)</measure>
    <time_frame>1 year</time_frame>
    <description>Leptin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satiety index</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Co-morbidities</measure>
    <time_frame>1 year</time_frame>
    <description>Diabetes, hypertension, hyperlipidemia</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Obesity</condition>
  <condition>Weight Loss</condition>
  <arm_group>
    <arm_group_label>Intervention Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the intervention arm will receive 300units of Botulinum Toxin A (Botox; Allergan Inc., Irvine, Ca, USA) diluted to 10mls of saline. Endoscopy will be performed using a single-lumen gastroscope. Injection of the solution will be done using a 23Gauge Interject needle catheter. 20 separate injections of 0.5ml each will be performed in a concentric ring 1cm apart. 10 injections will be performed into the body of the stomach, and 10 injections into the fundus, from the level of the CEJ and above
Patients will undergo a 12-week weight management program approximately 2 weeks after the injection of Botox.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will undergo a 12-week weight management program.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum toxin type A</intervention_name>
    <description>Intragastric injection of Botulinum toxin type A</description>
    <arm_group_label>Intervention Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Weight Management Program</intervention_name>
    <description>12 week weight management program</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>Intervention Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 21 to 65yrs old

          2. BMI &gt;32.5 (Class II obesity)

        Exclusion Criteria:

          1. Pregnancy or lactation

          2. Known pre-existing neuromuscular disorders or peripheral motor neuropathic disease
             (e.g. amyotrophic lateral sclerosis, motor neuropathy)

          3. Patients with known liver cirrhosis or known esophageal/gastric varices

          4. Known eating disorders

          5. Known major cardiovascular or pulmonary conditions

          6. Previous gastric/bariatric surgery

          7. Pathologic changes of the esophagus/stomach/duodenum demonstrated on endoscopy
             (esophagitis, peptic ulcers, cancer)

          8. Known alcohol or drug abuse

          9. Known allergy to any ingredients in Botox or allergic reaction to any other botulinum
             toxin product
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Danson Yeo, MBBS, MRCS, FRCS</last_name>
    <phone>+65 81834111</phone>
    <email>danson_xw_yeo@ttsh.com.sg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tan Tock Seng Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danson Yeo, MBBS</last_name>
      <phone>+65 81834111</phone>
      <email>danson_xw_yeo@ttsh.com.sg</email>
    </contact>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 16, 2020</study_first_submitted>
  <study_first_submitted_qc>February 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2020</study_first_posted>
  <last_update_submitted>February 17, 2020</last_update_submitted>
  <last_update_submitted_qc>February 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tan Tock Seng Hospital</investigator_affiliation>
    <investigator_full_name>Danson Yeo Xue Wei</investigator_full_name>
    <investigator_title>Associate Consultant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

